← Leaderboards
Jiong Li
University Of California Los Angeles
$1,696,835
Attributed
$1,696,835
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $746.2K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,696,835 · 3
By mechanism
R01$1,046,233 · 1
R21$417,557 · 1
R03$233,045 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Cun-Yu Wang$42,747,305
- Anh D Le$4,956,118
- Sean T Pianka$75,190
- Ashok Kumar$14,145,191
- Ichiro Nakano$7,010,147
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsGenesTumorigenesisMalignant NeoplasmsCancer TherapyEnhancersIn VitroPublic Health RelevanceFamily MemberFamilyGenetic TranscriptionHead And Neck Squamous Cell CarcinomaProteinsHpv NegativeHpv-Negative Head And Neck CancerInhibitorHead And Neck CancerProgramsFosl1 GeneMalignant - DescriptorMediatingNovel StrategiesEffective TherapyInvestigation
Grant awards (7)
FOSL1-super-enhancers define cisplatin-enriched cancer stem cells in HNSCC$528,240
R01 · FY2025 · DE · contact PI
Connecting liquid-liquid phase separation with super-enhancers and key oncogene transcription in HNSCC$189,372
R21 · FY2025 · DE · contact PI
FOSL1-super-enhancers define cisplatin-enriched cancer stem cells in HNSCC$517,993
R01 · FY2024 · DE · contact PI
Connecting liquid-liquid phase separation with super-enhancers and key oncogene transcription in HNSCC$228,185
R21 · FY2024 · DE · contact PI
BET bromodomain inhibition suppresses tumorigenesis and metastasis of HNSCC$91,706
R03 · FY2018 · DE · contact PI
BET bromodomain inhibition suppresses tumorigenesis and metastasis of HNSCC$24,964
R03 · FY2018 · DE · contact PI
BET bromodomain inhibition suppresses tumorigenesis and metastasis of HNSCC$116,375
R03 · FY2017 · DE · contact PI